CYTH News and Press, Cyclo Therapeutics Inc. From 10/18/22

– Data published in official journal of the Society for Inherited Metabolic Disorders, Molecular Genetics and Metabolism – Published trial data show that Trappsol ® Cyclo™ overcomes the NPC1 defect by removing trapped cholesterol from cells both s...

Patient enrollment and site activation now underway Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and inn...

– Company on track to commence enrollment and dosing of Phase 2 study of Trappsol ® Cyclo™ for the treatment of Alzheimer’s disease before year end – Ongoing advancement of global pivotal study (TransportNPC™) evaluating Trappsol &...

Summary Treatments such as Aricept and likely simufilam that inhibit the formation of the nitro-oxidant peroxynitrite and speed its decomposition stabilize Alzheimer's disease for about a year. Treatments (blarcamesine, Trappsol Cyclo, panax ginseng) that inhibit the formation of ...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...

Cyclo Therapeutics press release ( NASDAQ: CYTH ): Q2 GAAP EPS of -$0.41 beats by $0.12 . Revenue of $0.54M (+125.0% Y/Y) misses by $0.08M . For further details see: Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M ...

– On track to commence Phase 2 study of Trappsol ® Cyclo™ for the treatment of Alzheimer’s Disease before year end – Continued execution on advancement of lead development program evaluating Trappsol ® Cyclo™ for Niemann-Pic...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...

INmune Bio and Alector are seeking to treat Alzheimer's disease by decreasing neuroinflammation while maintaining a healthy immune response. However, neither company's drug candidate appears to address the oxidative stress that precedes neuroinflammation. Anti-inflammatory drug ca...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...